Assetmark Inc. reduced its stake in shares of Sanofi SA (NYSE:SNY) by 1.3% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 145,314 shares of the company’s stock after selling 1,879 shares during the quarter. Assetmark Inc.’s holdings in Sanofi were worth $6,288,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors and hedge funds also recently modified their holdings of SNY. Ibex Wealth Advisors purchased a new stake in shares of Sanofi in the second quarter valued at about $25,000. Heritage Wealth Advisors lifted its stake in shares of Sanofi by 141.2% during the second quarter. Heritage Wealth Advisors now owns 603 shares of the company’s stock valued at $26,000 after buying an additional 353 shares during the period. Bessemer Group Inc. lifted its stake in shares of Sanofi by 292.4% during the second quarter. Bessemer Group Inc. now owns 671 shares of the company’s stock valued at $29,000 after buying an additional 500 shares during the period. Evolution Wealth Advisors LLC purchased a new position in shares of Sanofi during the second quarter valued at approximately $40,000. Finally, Massey Quick Simon & CO. LLC purchased a new position in shares of Sanofi during the second quarter valued at approximately $43,000. Institutional investors own 7.04% of the company’s stock.
Several equities analysts recently commented on the stock. Morgan Stanley raised shares of Sanofi from an “equal” rating to a “weight” rating in a research report on Friday, September 20th. Guggenheim raised shares of Sanofi from a “neutral” rating to a “buy” rating in a research report on Monday, September 23rd. Zacks Investment Research raised shares of Sanofi from a “hold” rating to a “buy” rating and set a $47.00 price target for the company in a research report on Thursday, August 29th. Jefferies Financial Group reissued a “buy” rating on shares of Sanofi in a research report on Thursday, August 29th. Finally, TheStreet raised shares of Sanofi from a “c+” rating to a “b-” rating in a research report on Friday, June 21st. Four analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Sanofi currently has a consensus rating of “Buy” and a consensus target price of $49.67.
SNY traded up $0.11 during trading hours on Friday, reaching $44.95. 691,870 shares of the stock traded hands, compared to its average volume of 1,309,806. Sanofi SA has a fifty-two week low of $40.00 and a fifty-two week high of $47.11. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.22 and a quick ratio of 0.85. The company has a market cap of $112.56 billion, a price-to-earnings ratio of 14.36, a PEG ratio of 2.41 and a beta of 0.67. The firm’s fifty day simple moving average is $44.58 and its two-hundred day simple moving average is $43.01.
Sanofi (NYSE:SNY) last posted its quarterly earnings data on Monday, July 29th. The company reported $0.74 EPS for the quarter, beating the Zacks’ consensus estimate of $0.67 by $0.07. Sanofi had a net margin of 12.20% and a return on equity of 18.18%. The firm had revenue of $8.63 billion for the quarter, compared to the consensus estimate of $8.42 billion. During the same period in the prior year, the firm posted $1.25 EPS. The firm’s revenue was up 5.5% compared to the same quarter last year. On average, research analysts predict that Sanofi SA will post 3.1 earnings per share for the current year.
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
Recommended Story: What is the outlook for the FAANG stocks?
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.